Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection Original Article, N Engl J Med 2009:361;580-593.. In the first sentence of the Study Design subsection in Methods (page 581), the two levels of stratification according to hepatitis C virus (HCV) RNA levels given parenthetically should have been expressed as IU per milliliter, not as IU per cubic millimeter. In the first sentence of the Efficacy Assessments subsection in Methods (page 582), the lower limit of quantitation should have been 27 IU per milliliter, not 27 IU per cubic millimeter. In the Efficacy subsection of Results, the two mentions of HCV RNA levels (pages 583 and 584) should have been expressed as IU per milliliter rather than as IU per cubic millimeter. In the footnotes under Table 1 (page 585), the footnote designated by a double dagger should have expressed HCV RNA as IU per milliliter rather than as IU per cubic millimeter. In the footnotes under Table 2 (page 587), the footnote designated by an asterisk should have expressed HCV RNA as IU per milliliter rather than as IU per cubic millimeter. In the footnotes under Table 3 (page 589), the footnote designated by an asterisk should have expressed the lower limit of detection as 27 IU per milliliter, not 27 IU per cubic millimeter. We regret the errors. The article has been corrected at NEJM.org.